Major Depressive Disorder is a condition that lowers a person’s mood, self-esteem, motivation and limits their general ability to enjoy pleasurable activities.

Depression prevents over 1 million people in Ontario from forming strong relationships, sleeping, eating, and is the number one cause of disability worldwide. The direct and indirect costs to Ontario are over $12.5 billion every year.

The Ontario Brain Institute challenged neuroscientists across the province to come up with a new approach to addressing depression, in the context of an Integrated Discovery program. “Integrated Discovery” is a unique template, developed by the OBI, which brings together researchers, clinicians, industry and patient advocates to maximize fresh insights and speed translation of those insights into better care.


The Canadian Biomarkers in Depression (CAN-BIND) Integrated Discovery Program is a research-based innovative initiative designed to improve the diagnosis and treatment of depression. The program’s mandate is to ensure that discoveries are transformed into new diagnostics, treatments and improved clinical practice. The emphasis is on translational science and involves a province-wide collaboration between Ontario’s world-class depression researchers and clinicians, patient advocacy groups and the industrial sector.  This collaborative initiative is also engaging partner sites across Canada in an effort to bridge the translational gap and to better predict treatment selection and outcomes. The goal of CAN-BIND is to develop tools to get patients the right treatment the first time.

Visit the CAN-BIND website


Watch the CAN-BIND video:


Reduced brain volume in major depressive disorder, MRICredit: Dr Matthew J Kempton, KCL. Wellcome Images